SCHEMBL6578218

SCHEMBL6578218

CCCCOC(=O)N1CC(O)C(NC(=O)[C@H](CC(C)C)NC(=O)OCc2ccncc2)C1

nearest known ligand 0.67

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
CTSK P43235 20/20 0.67
CTSL P07711 11/20 0.51
CTSS P25774 7/20 0.49
CTSB P07858 3/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6580419 0.90 CTSK (0.83) CTSKCTSLCTSSCTSB
SCHEMBL6582049 0.89 CTSK (0.70) CTSKCTSLCTSSCTSB
SCHEMBL6581062 0.89 CTSK (0.72) CTSKCTSLCTSSCTSB
SCHEMBL6580163 0.87 CTSK (0.68) CTSKCTSLCTSSCTSB
SCHEMBL6583067 0.86 CTSK (0.90) CTSKCTSLCTSSCTSB
SCHEMBL6580647 0.86 CTSK (0.69) CTSKCTSLCTSSCTSB
SCHEMBL6578277 0.84 CTSK (0.63) CTSKCTSLCTSSCTSB
SCHEMBL6580204 0.83 CTSK (0.75) CTSKCTSLCTSSCTSB
SCHEMBL6580487 0.81 CTSK (0.62) CTSKCTSLCTSSCTSB
SCHEMBL6580333 0.81 CTSK (0.76) CTSKCTSLCTSSCTSB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0936912-B1 INHIBITORS OF CYSTEINE PROTEASE SMITHKLINE BEECHAM CORP (US) 2004-02-11 EP claimed
US-20020128476-A1 Inhibitors of cysteine protease SMITHKLINE BEECHAM CORPORATION 2002-09-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020128476-A1 Inhibitors of cysteine protease CTRC, RCE1, CTRL CTSK 100/4885CTSL 8/4885CTSS 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.